Prostatype Genomics publishes newsletter on US progress and the long-term follow-up study in Uppsala
Prostatype Genomics today publishes a newsletter for January–February 2024 with a CEO interview on what the three recently published advances in the United States mean for the company from an investor perspective, as well as an in-depth interview about the ongoing long-term follow-up study with Prostatype®, the company's gene test for prostate cancer patients, at Uppsala University Hospital.CEO Fredrik Persson explains the significance of the recently achieved milestones on the way to the US marketFredrik explains the significance of the three milestones achieved in the United States in